Paul F Pinsky1, Eric Miller1, Philip Prorok1, Robert Grubb2, E David Crawford3, Gerald Andriole4. 1. Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, MD, USA. 2. Medical University of South Carolina, Charleston, SC, USA. 3. University of Colorado Health Sciences, Denver, CO, USA. 4. Washington University School of Medicine, St. Louis, MO, USA.
Abstract
OBJECTIVE: To examine prostate cancer (PCa) incidence and mortality by arm in the randomized Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. PATIENTS AND METHODS: Patients aged 55-74 years at 10 screening centres were randomized between 1993 and 2001 to an intervention or usual care arm. Patients in the intervention arm received six annual prostate-specific antigen (PSA) tests and four annual digital rectal examinations. The patients were followed for PCa incidence and for mortality via active follow-up processes and by linkage to state cancer registries and the National Death Index. For cancers identified through active follow-up, trial abstractors recorded the mode of diagnosis (screen-detected, symptomatic, other). RESULTS:A total of 38 340 patients were randomized to the intervention arm and 38 343 to a usual care arm. The median follow-up for mortality was 16.9 (intervention) and 16.7 years (usual care). There were 333 (intervention) and 352 (usual care) PCa cancer deaths, giving rates (per 10 000 person-years) of 5.5 and 5.9, respectively, and a rate ratio (RR) of 0.93 (95% confidence interval [CI] 0.81-1.08; P = 0.38). The RR for overall PCa incidence was 1.05 (95% CI 1.01-1.09). The RRs by Gleason category were 1.17 (95% CI 1.11-1.23) for Gleason 2-6, 1.00 (95% CI 0.93-1.07) for Gleason 7 and 0.89 (95% CI 0.80-0.99) for Gleason 8-10 disease. By mode of detection, during the trial's screening phase, 13% of intervention arm vs 27% of usual care arm cases were symptomatic; post-screening, these percentages were 18% in each arm. CONCLUSION: After almost 17 years of median follow-up, there was no significant reduction in PCa mortality in the intervention compared with the usual care arm. There was a significant increase in Gleason 2-6 disease and a significant reduction in Gleason 8-10 disease in the intervention compared with the usual care arm.
RCT Entities:
OBJECTIVE: To examine prostate cancer (PCa) incidence and mortality by arm in the randomized Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial. PATIENTS AND METHODS: Patients aged 55-74 years at 10 screening centres were randomized between 1993 and 2001 to an intervention or usual care arm. Patients in the intervention arm received six annual prostate-specific antigen (PSA) tests and four annual digital rectal examinations. The patients were followed for PCa incidence and for mortality via active follow-up processes and by linkage to state cancer registries and the National Death Index. For cancers identified through active follow-up, trial abstractors recorded the mode of diagnosis (screen-detected, symptomatic, other). RESULTS: A total of 38 340 patients were randomized to the intervention arm and 38 343 to a usual care arm. The median follow-up for mortality was 16.9 (intervention) and 16.7 years (usual care). There were 333 (intervention) and 352 (usual care) PCa cancer deaths, giving rates (per 10 000 person-years) of 5.5 and 5.9, respectively, and a rate ratio (RR) of 0.93 (95% confidence interval [CI] 0.81-1.08; P = 0.38). The RR for overall PCa incidence was 1.05 (95% CI 1.01-1.09). The RRs by Gleason category were 1.17 (95% CI 1.11-1.23) for Gleason 2-6, 1.00 (95% CI 0.93-1.07) for Gleason 7 and 0.89 (95% CI 0.80-0.99) for Gleason 8-10 disease. By mode of detection, during the trial's screening phase, 13% of intervention arm vs 27% of usual care arm cases were symptomatic; post-screening, these percentages were 18% in each arm. CONCLUSION: After almost 17 years of median follow-up, there was no significant reduction in PCa mortality in the intervention compared with the usual care arm. There was a significant increase in Gleason 2-6 disease and a significant reduction in Gleason 8-10 disease in the intervention compared with the usual care arm.
Authors: John Thomas Helgstrand; Martin Andreas Røder; Nina Klemann; Birgitte Grønkær Toft; Klaus Brasso; Ben Vainer; Peter Iversen Journal: Eur J Cancer Date: 2017-08-02 Impact factor: 9.162
Authors: Paul F Pinsky; Amanda Blacka; Barnett S Kramer; Anthony Miller; Philip C Prorok; Christine Berg Journal: Clin Trials Date: 2010-06-22 Impact factor: 2.486
Authors: Simon Chowdhury; David Robinson; Declan Cahill; Alejo Rodriguez-Vida; Lars Holmberg; Henrik Møller Journal: BJU Int Date: 2013-07 Impact factor: 5.588
Authors: Richard M Martin; Jenny L Donovan; Emma L Turner; Chris Metcalfe; Grace J Young; Eleanor I Walsh; J Athene Lane; Sian Noble; Steven E Oliver; Simon Evans; Jonathan A C Sterne; Peter Holding; Yoav Ben-Shlomo; Peter Brindle; Naomi J Williams; Elizabeth M Hill; Siaw Yein Ng; Jessica Toole; Marta K Tazewell; Laura J Hughes; Charlotte F Davies; Joanna C Thorn; Elizabeth Down; George Davey Smith; David E Neal; Freddie C Hamdy Journal: JAMA Date: 2018-03-06 Impact factor: 56.272
Authors: Melissa Assel; Anders Dahlin; David Ulmert; Anders Bergh; Pär Stattin; Hans Lilja; Andrew J Vickers Journal: Eur Urol Date: 2017-10-21 Impact factor: 20.096
Authors: Paul F Pinsky; Philip C Prorok; Kelly Yu; Barnett S Kramer; Amanda Black; John K Gohagan; E David Crawford; Robert L Grubb; Gerald L Andriole Journal: Cancer Date: 2016-12-01 Impact factor: 6.860
Authors: Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen Journal: N Engl J Med Date: 2009-03-18 Impact factor: 91.245
Authors: Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg Journal: N Engl J Med Date: 2009-03-18 Impact factor: 91.245
Authors: Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen Journal: Lancet Date: 2014-08-06 Impact factor: 79.321
Authors: Paul F Pinsky; Amanda Black; Sarah E Daugherty; Robert Hoover; Howard Parnes; Zachary L Smith; Scott Eggener; Gerald L Andriole; Sonja I Berndt Journal: Cancer Date: 2019-05-08 Impact factor: 6.860
Authors: Tunde M Adebola; Herman W W Fennell; Michael D Druitt; Carolina A Bonin; Victoria A Jenifer; Andre J van Wijnen; Eric A Lewallen Journal: Curr Mol Biol Rep Date: 2022-03-11
Authors: Xiaoyu Song; Meng Ru; Zoe Steinsnyder; Kaitlyn Tkachuk; Ryan P Kopp; John Sullivan; Zeynep H Gümüş; Kenneth Offit; Vijai Joseph; Robert J Klein Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-07-01 Impact factor: 4.090
Authors: Maria Frånlund; Marianne Månsson; Rebecka Arnsrud Godtman; Gunnar Aus; Erik Holmberg; Karin Stinesen Kollberg; Pär Lodding; Carl-Gustaf Pihl; Johan Stranne; Hans Lilja; Jonas Hugosson Journal: J Urol Date: 2022-04-15 Impact factor: 7.600
Authors: Evan Kovac; Sigrid V Carlsson; Hans Lilja; Jonas Hugosson; Michael W Kattan; Erik Holmberg; Andrew J Stephenson Journal: JAMA Netw Open Date: 2020-01-03